InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
1.330
-0.020 (-1.48%)
Oct 2, 2026, 4:00 PM EDT - Market closed
InMed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| - | - | 4.6 | 4.14 | 1.09 | |
Revenue Growth | - | - | 11.18% | 279.61% | - |
Cost of Revenue | - | - | 3.5 | 2.73 | 0.55 |
Gross Profit | - | - | 1.1 | 1.4 | 0.54 |
Selling, General & Admin | 6.66 | 5.41 | 5.8 | 5.85 | 6.67 |
Research & Development | 3.03 | 2.82 | 3.22 | 3.73 | 7.28 |
Operating Expenses | 9.9 | 8.45 | 9.24 | 9.78 | 14.14 |
Operating Income | -9.9 | -8.45 | -8.13 | -8.38 | -13.59 |
Interest Expense | -0.01 | -0.37 | - | - | - |
Interest & Investment Income | 0.24 | 0.16 | 0.53 | 0.49 | 0.1 |
Currency Exchange Gain (Loss) | -0.06 | -0.03 | -0.06 | -0.05 | -0.12 |
EBT Excluding Unusual Items | -9.72 | -8.69 | -7.67 | -7.93 | -13.61 |
Merger & Restructuring Charges | - | - | - | - | -0.2 |
Impairment of Goodwill | - | - | - | - | -2.02 |
Gain (Loss) on Sale of Assets | -0.01 | - | - | - | - |
Asset Writedown | -1.65 | - | - | - | -1.45 |
Other Unusual Items | - | - | - | - | -1.31 |
Pretax Income | -11.37 | -8.69 | -7.67 | -7.93 | -18.6 |
Income Tax Expense | - | - | 0.01 | 0.01 | - |
Earnings From Continuing Operations | -11.37 | -8.69 | -7.68 | -7.95 | -18.6 |
Earnings From Discontinued Operations | -1.19 | 0.53 | - | - | - |
Net Income | -12.56 | -8.16 | -7.68 | -7.95 | -18.6 |
Preferred Dividends & Other Adjustments | 0.43 | - | - | - | - |
Net Income to Common | -12.99 | -8.16 | -7.68 | -7.95 | -18.6 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 4 | 1 | 0 | 0 | 0 |
Shares Change | 326.64% | 156.11% | 211.26% | 336.59% | 108.64% |
EPS (Basic) | -3.12 | -8.36 | -20.14 | -64.92 | -663.32 |
EPS (Diluted) | -3.12 | -8.36 | -20.14 | -64.92 | -663.32 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -8.64 | -8.1 | -7 | -7.45 | -15.62 |
Free Cash Flow Per Share | -2.08 | -8.30 | -18.36 | -60.81 | -557.14 |
Gross Margin | - | - | 23.95% | 33.93% | 49.89% |
Operating Margin | - | - | -176.92% | -202.60% | -1247.60% |
Profit Margin | - | - | -166.94% | -192.18% | -1707.32% |
Free Cash Flow Margin | - | - | -152.14% | -180.02% | -1434.03% |
EBITDA | -9.69 | -8.24 | -7.91 | -8.18 | -13.41 |
EBITDA Margin | - | - | -172.15% | -197.71% | - |
D&A For EBITDA | 0.21 | 0.21 | 0.22 | 0.2 | 0.19 |
EBIT | -9.9 | -8.45 | -8.13 | -8.38 | -13.59 |
EBIT Margin | - | - | -176.92% | -202.60% | - |